Croissy-Beaubourg, April 9 2013 - Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company specializing in theranostic and in vitro diagnostics, today announced it has been granted financial support by Oséo, the French Agency for Innovation, for its participation in CaReNA. Total development costs for the entire project could reach €18 M. CaReNA is a collaborative project between Splicos, alternative RNA splicing specialist and project-lead, Theradiag and the CNRS (French National Center for Research and Science) for the development of RNA-targeting therapeutic and diagnostic solutions in the treatment of HIV/AIDS and obesity. As part of the project, Theradiag will receive €1.2 million for developing and implementing 4 new diagnostic kits.
Theradiag will develop 2 new companion diagnostic kits to Splicos’ therapeutics, one for the treatment of HIV /AIDS and another for the monitoring of diabetes and associated metabolic disorders. These tests will be implemented right from the clinical development phases and will enable physicians to optimize patient care (as part of the theranostic strategy). A third test will be developed for early monitoring of HIV infection and disease evolution. A fourth test will allow for the assessment of patient response and/or resistance to antiretroviral treatments through the quantification of predicting miRNAs.
“We are thrilled by this partnership with Splicos and CNRS. The support granted by Oséo for this project lends validation to our strategic development goal based on providing innovative theranotics through our miRNA platform. This new financing will allow us to expand our theranostic range with 4 new molecular biology/miRNA diagnostic kits, adding on to the existing 7 blood-test kits of the Lisa Tracker portfolio. We are now positioning ourselves as true leaders of miRNA diagnostics. With these new kits, we will be able to tap into the broad diagnostic markets of HIV/AIDS and metabolic disorders” concluded Michel Finance, CEO of Theradiag.
About Theradiag
Backed by its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostic tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of “customized treatment”, which favors the individualization of treatments, the evaluation of their efficiency and the prevention of drug resistance. Theradiag markets the Lisa-Tracker range (CE marked), which is a comprehensive multiparameter diagnosis solution for patients with autoimmune diseases treated with biotherapies. Theradiag is also developing new diagnostic markers thanks to its microRNA platform, which will allow specific biomarkers to be identified in order to guide therapy and will be first and foremost applied to the treatment of AIDS. The Company is based in Marne-la-Vallée, near Paris, and in Montpellier, and has some 50 employees.
For more information about Theradiag, please visit our website: www.theradiag.com
Theradiag
Investor Relations
Nathalie Trepo
Tél: 01 64 62 10 12
ntrepo@theradiag.com
NewCap.
Financial Communications
and investor relations
Valentine Brouchot /
Pierre Laurent
Tél. : 01 44 71 98 52
theradiag@newcap.fr
Alize RP
Press
Caroline Carmagnol
caroline@alizerp.com
Tél. : 06 64 18 99 59
Christian Berg
christian@alizerp.com
Tél. : 01 42 68 86 41
